Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002975181 | SCV003279577 | benign | not provided | 2023-12-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004617131 | SCV005120103 | uncertain significance | Inborn genetic diseases | 2024-03-25 | criteria provided, single submitter | clinical testing | The c.400T>A (p.S134T) alteration is located in exon 3 (coding exon 3) of the EXPH5 gene. This alteration results from a T to A substitution at nucleotide position 400, causing the serine (S) at amino acid position 134 to be replaced by a threonine (T). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004758246 | SCV005353835 | likely benign | EXPH5-related disorder | 2024-06-20 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |